1. Antiepileptics

   Case report 01 October 2022 Pages: 51 - 51

2. Antiglaucoma/acetazolamide/bevacizumab

   Case report 01 October 2022 Pages: 52 - 52

3. Antineoplastics

   Case report 01 October 2022 Pages: 53 - 53

4. Antineoplastics

   Case report 01 October 2022 Pages: 54 - 54

5. Antineoplastics

   Case report 01 October 2022 Pages: 55 - 55

6. Antineoplastics

   Case report 01 October 2022 Pages: 56 - 56

7. Antineoplastics

   Case report 01 October 2022 Pages: 57 - 57

8. Antineoplastics

   Case report 01 October 2022 Pages: 58 - 58

9. Antineoplastics

   Case report 01 October 2022 Pages: 59 - 59

10. Antineoplastics

    Case report 01 October 2022 Pages: 60 - 60

11. Antineoplastics

    Case report 01 October 2022 Pages: 61 - 61

12. Antineoplastics

    Case report 01 October 2022 Pages: 62 - 62

13. Antineoplastics

    Case report 01 October 2022 Pages: 63 - 63

14. Antineoplastics

    Case report 01 October 2022 Pages: 64 - 64

15. Antineoplastics

    Case report 01 October 2022 Pages: 65 - 65

16. Antineoplastics

    Case report 01 October 2022 Pages: 66 - 66

17. Antineoplastics

    Case report 01 October 2022 Pages: 67 - 67

18. Antineoplastics

    Case report 01 October 2022 Pages: 68 - 68

19. Antineoplastics

    Case report 01 October 2022 Pages: 69 - 69

20. Antineoplastics

    Case report 01 October 2022 Pages: 70 - 70

21. Antineoplastics

    Case report 01 October 2022 Pages: 71 - 71

22. Antineoplastics

    Case report 01 October 2022 Pages: 72 - 72

23. Antineoplastics

    Case report 01 October 2022 Pages: 73 - 73

24. Antineoplastics/eculizumab/immunosuppressants

    Case report 01 October 2022 Pages: 74 - 74

25. Antineoplastics/enoxaparin-sodium

    Case report 01 October 2022 Pages: 75 - 75

26. Antineoplastics/entecavir

    Case report 01 October 2022 Pages: 76 - 76

27. Antineoplastics/epidermal-growth-factor-receptor-antagonists

    Case report 01 October 2022 Pages: 77 - 77

28. Antineoplastics/immunosuppressants

    Case report 01 October 2022 Pages: 78 - 78

29. Antineoplastics/loperamide

    Case report 01 October 2022 Pages: 79 - 79

30. Antineoplastics/loperamide/octreotide

    Case report 01 October 2022 Pages: 80 - 80

31. Antiplatelets/aspirin/heparin

    Case report 01 October 2022 Pages: 81 - 81

32. Antipsychotics

    Case report 01 October 2022 Pages: 82 - 82

33. Antiretrovirals

    Case report 01 October 2022 Pages: 83 - 83

34. Antirheumatics/glucocorticoids

    Case report 01 October 2022 Pages: 84 - 84

35. Antivirals/clarithromycin/tacrolimus

    Case report 01 October 2022 Pages: 85 - 85

36. Anxiolytics

    Case report 01 October 2022 Pages: 86 - 86

37. Apalutamide

    Case report 01 October 2022 Pages: 87 - 87

38. Argatroban/AZD-1222/immune-globulin

    Case report 01 October 2022 Pages: 88 - 88

39. Aripiprazole-lauroxil

    Case report 01 October 2022 Pages: 89 - 89

40. Aripiprazole/lurasidone

    Case report 01 October 2022 Pages: 90 - 90

41. Arsenic trioxide/tretinoin

    Case report 01 October 2022 Pages: 91 - 91

42. Arsenic-trioxide

    Case report 01 October 2022 Pages: 92 - 92

43. Ascorbic acid/methylthioninium chloride

    Case report 01 October 2022 Pages: 93 - 93

44. Aspirin

    Case report 01 October 2022 Pages: 94 - 94

45. Aspirin/clopidogrel

    Case report 01 October 2022 Pages: 95 - 95

46. Aspirin/clopidogrel

    Case report 01 October 2022 Pages: 96 - 96

47. Aspirin/clopidogrel/favipiravir interaction

    Case report 01 October 2022 Pages: 97 - 97

48. Aspirin/dabigatran-etexilate

    Case report 01 October 2022 Pages: 98 - 98

49. Aspirin/warfarin

    Case report 01 October 2022 Pages: 99 - 99

50. Atezolizumab/bevacizumab/ramucirumab

    Case report 01 October 2022 Pages: 100 - 100